CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $10.65M, lower than 95% of all stocks globally
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.59BCNY1.72B · vs all stocks (USD)
Revenue (TTM)
71.64MCNY10.65M · vs all stocks (USD)
Beta
0.2560xvs all stocks
52-Week Change
-52.32%vs all stocks
Market Capitalization
11.59BCNY1.72B · vs all stocks (USD)
Enterprise Value
10.42BCNY1.55B · vs all stocks (USD)
Forward P/E
-65.48xvs Biotechnology peers
Price to Book (MRQ)
8.36xvs Biotechnology peers
Enterprise to Revenue
145.49xvs Biotechnology peers
Enterprise to EBITDA
-31.37xvs Biotechnology peers
Gross Margin
96.17%vs Biotechnology peers
Operating Margin
-117.00%vs Biotechnology peers
Return on Assets (TTM)
-12.12%vs Biotechnology peers
Return on Equity (TTM)
-18.60%vs Biotechnology peers
Revenue (TTM)
71.64MCNY10.65M · vs all stocks (USD)
Revenue per Share (TTM)
0.1250CNYUpdated Aug 21, 2026Quarterly Revenue Growth
419.50%vs Biotechnology peers
Gross Profit (TTM)
66.15MCNY9.84M · vs all stocks (USD)
EBITDA (TTM)
-332.26MCNY-49.41M · vs all stocks (USD)
Net Income (TTM)
-303.73MCNY-45.17M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-71.57%vs Biotechnology peers
Operating Cash Flow (TTM)
-236.05MCNY-35.10M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-138.17MCNY-20.55M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
37.29MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
5.02MCNYFY2025 · Dec 31, 2025Gross Profit
32.27MCNYFY2025 · Dec 31, 2025Operating Income
-330.07MCNY-49.08M · vs all stocks (USD)
Pre-tax Income
-316.63MCNYFY2025 · Dec 31, 2025Income Tax Expense
239.53KCNYFY2025 · Dec 31, 2025Net Income
-316.87MCNYFY2025 · Dec 31, 2025EBIT
-315.79MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-291.15MCNYFY2025 · Dec 31, 2025Research & Development
325.79MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
29.25MCNYFY2025 · Dec 31, 2025Other Operating Expenses
113.62KCNYFY2025 · Dec 31, 2025Non-operating Interest Income
24.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
835.12KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.5500CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.5500CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
576.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
576.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-316.87MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-268.70MCNYFY2025 · Dec 31, 2025Free Cash Flow
-275.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
723.12MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-316.87MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-10.75MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
58.69MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
239.53KCNYFY2025 · Dec 31, 2025Capital Expenditures
-6.92MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.30BCNYFY2025 · Dec 31, 2025Sale of Investments
1.28BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-26.33MCNYFY2025 · Dec 31, 2025Other Financing Charges
-6.22MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-6.22MCNYFY2025 · Dec 31, 2025Shares Outstanding
578.35MSharesUpdated Aug 21, 2026Float Shares
397.63MSharesUpdated Aug 21, 2026% Held by Insiders
31.20%vs all stocks
% Held by Institutions
24.10%vs all stocks
Total Cash (MRQ)
1.38BCNY204.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.38CNYUpdated Aug 21, 2026Total Debt (MRQ)
19.97MCNY2.97M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0134xvs Biotechnology peers
Current Ratio (MRQ)
17.36xvs Biotechnology peers
Book Value per Share (MRQ)
2.59CNYUpdated Aug 21, 2026Total Assets
1.70BCNY253.38M · vs all stocks (USD)
Total Current Assets
1.65BCNYFY2025 · Dec 31, 2025Total Liabilities
167.73MCNYFY2025 · Dec 31, 2025Total Non-current Assets
52.61MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
18.83MCNYFY2025 · Dec 31, 2025Total Current Liabilities
148.90MCNYFY2025 · Dec 31, 2025Cash
723.11MCNYFY2025 · Dec 31, 2025Cash Equivalents
657.81MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.38BCNYFY2025 · Dec 31, 2025Other Short-term Investments
153.68MCNYFY2025 · Dec 31, 2025Accounts Receivable
84.67MCNYFY2025 · Dec 31, 2025Accounts Payable
115.48MCNYFY2025 · Dec 31, 2025Short-term Debt
7.15MCNYFY2025 · Dec 31, 2025Other Current Liabilities
873.87KCNYFY2025 · Dec 31, 2025Long-term Debt
14.92MCNYFY2025 · Dec 31, 2025Common Stock (Book)
578.35MCNYFY2025 · Dec 31, 2025Retained Earnings
-2.86BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.54BCNY228.44M · vs all stocks (USD)
52-Week Low
15.58CNYUpdated Aug 21, 202652-Week High
45.50CNYUpdated Aug 21, 202652-Week Change
-52.32%vs all stocks
Beta
0.2560xvs all stocks
50-Day MA
20.71CNYUpdated Aug 21, 2026200-Day MA
23.10CNYUpdated Aug 21, 2026Avg 10-Day Volume
22.34MSharesUpdated Aug 21, 2026Avg 30-Day Volume
23.56MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.5300CNYUpdated Aug 21, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $10.65M, lower than 95% of all stocks globallySignificant
Revenue (USD): 10,654,038.858Global P5: 30,274,777.221
Market cap is $1.72B, above the global median of $1.15BNotable
Market cap (USD): 1,723,822,538.297Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
AnaptysBio Inc.
Tier 1ProductionApproval-Gated PipelineRiskInterface
MapLight Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Butterfly Network Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Taysha Gene Therapies Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Harrow Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Vital Farms Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownIndustry-Benchmarked ROA and Margin Elevated
Arqit Quantum Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsDecline With Range Expansion And Drawdown
CrowdStrike Holdings Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total AssetsDecline With Range Expansion And Drawdown